COGT

Cogent Biosciences is a clinical-stage biotech built almost entirely around bezuclastinib, a selective KIT-mutant inhibitor headed toward FDA submission and commercial launch (for systemic mastocytosis and gastrointestinal stromal tumor indications). The company has effectively no product revenue, and the financials are pure development burn: a $329M net loss (widening 28.6%), a -$333M operating loss, -$264M of operating cash flow, and R&D spend of $270M (+16.0%) as it funds pivotal programs. The negative-thousands operating margin and -51.7% ROE confirm there is no business to value on fundamentals yet — this is a probability-weighted bet on a single asset.

Liquidity is a strength. A large raise lifted total assets 185.9% to $938M (current assets of $910M) and equity 148.3% to $636M, against modest liabilities including $223M of long-term debt (0.47x leverage). That funds the path to launch, but it came at a cost: shares outstanding rose 42.6%, and the 10-K warns of further dilution risk as the company raises capital to complete development and commercialization.